Advertisement

Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients

  • Richard Ofner
  • Cathrin Ritter
  • Barbara Heidenreich
  • Rajiv Kumar
  • Selma Ugurel
  • David Schrama
  • Jürgen C. BeckerEmail author
Original Article – Cancer Research

Abstract

Background

TERT promoter mutations were detected at high frequencies in several cancer types including melanoma. Previous reports showed that these recurrent mutations increase TERT gene expression and the use of TERT mutation status as prognostic factor was suggested.

Objectives

Here we screen a panel of 115 melanoma tumor samples from Austrian patients to evaluate the prevalence and distribution of TERT promoter mutations. The association with clinical and tumor characteristics and the effect on overall survival was analyzed.

Methods

Genomic DNA from formalin-fixed paraffin-embedded tumor samples was isolated followed by PCR amplification, Sanger sequencing and statistical analysis.

Results

We identified TERT promoter mutations in 63 of 115 (54.8%) tumor samples. No statistical significant difference in mutation frequency between primary (22/40 [55%]) and metastatic lesions (41/75 [54.7%]) was detected. BRAF-/NRAS-mutated tumors showed a higher frequency of TERT mutations (pT OR 2.24, 95% CI 0.56–9.02, p = 0.3) (met OR 2.74, 95% CI 0.98–7.66, p = 0.05). In primary melanoma, the presence of alterations in TERT was associated with the carrier status of a common single-nucleotide polymorphism rs2853669 (OR 4.55, CI 1.18–17.52, p = 0.03). In this patient cohort, TERT promoter mutations were not associated with clinical characteristics such as the presence of ulceration or Breslow thickness or showed an effect on overall survival.

Conclusion

Alterations in the TERT promoter region are one of the most frequent mutations in melanoma. Based on this analysis and preliminary evidence, prospective studies will be needed to evaluate the reliability of TERT promoter mutations as prognostic factors in melanoma.

Keywords

Melanoma TERT promotor mutation Primary tumor Metastatic lesion 

Notes

Acknowledgements

We thank Lorenzo Cerroni and Isabella Fried (Department of General Dermatology, Medical University Graz, Graz, Austria) for supporting this study and Gerlinde Mayer and Ulrike Schmidbauer (Department of General Dermatology, Medical University Graz, Graz, Austria) for excellent technical assistance.

Funding

This study was funded by the FWF graduate school DK MOLIN.

Compliance with ethical standards

Conflict of interest

The authors RO, CR, BH, RK and DS state no conflict of interest. Author SU has received a honorarium from Roche for attending an advisory board. Author JCB has received speaker honorariums from Amgen, MerckSerono and Pfizer, advisory board honorariums from Amgen, MerckSerono, MSD, Novartis and Takeda as well as research funding from Boehringer Ingelheim, BMS and MerckSerono; none of these activities are related to the submitted report.

Ethics approval

The study was approved by the institutional review board of the Medical University of Graz (ethics votum 24-292 ex 11/12). Informed consent: Informed consent was obtained from all individual participants included in the study.

References

  1. Begus-Nahrmann Y et al (2012) Transient telomere dysfunction induces chromosomal instability and promotes carcinogenesis. J Clin Investig 122:2283–2288. doi: 10.1172/JCI61745 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bernardes de Jesus B, Blasco MA (2013) Telomerase at the intersection of cancer and aging. Trends Genet 29:513–520. doi: 10.1016/j.tig.2013.06.007 CrossRefPubMedGoogle Scholar
  3. Bhalla K et al (2011) PGC1α promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res 71:6888–6898. doi: 10.1158/0008-5472.CAN-11-1011 CrossRefPubMedPubMedCentralGoogle Scholar
  4. Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D (2015) Cancer-associated TERT promoter mutations abrogate telomerase silencing. eLife. doi: 10.7554/eLife.07918 Google Scholar
  5. Griewank KG et al (2014) TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst. doi: 10.1093/jnci/dju246 PubMedCentralGoogle Scholar
  6. Heidenreich B et al (2014) Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma Nature. Communications. doi: 10.1038/ncomms4401 Google Scholar
  7. Hodis E et al (2012) A landscape of driver mutations in melanoma. Cell 150:251–263. doi: 10.1016/j.cell.2012.06.024 CrossRefPubMedPubMedCentralGoogle Scholar
  8. Horn S et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959–961. doi: 10.1126/science.1230062 CrossRefPubMedGoogle Scholar
  9. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957–959. doi: 10.1126/science.1229259 CrossRefPubMedPubMedCentralGoogle Scholar
  10. Ko E, H-w Seo, Jung ES, B-h Kim, Jung G (2015) The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer vol 7. Impact J. doi: 10.18632/oncotarget.6331 Google Scholar
  11. Krauthammer M et al (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44:1006–1014. doi: 10.1038/ng.2359 CrossRefPubMedPubMedCentralGoogle Scholar
  12. Kubic JD, Little EC, Lui JW, Iizuka T, Lang D (2015) PAX3 and ETS1 synergistically activate MET expression in melanoma cells. Oncogene 34:4964–4974. doi: 10.1038/onc.2014.420 CrossRefPubMedGoogle Scholar
  13. Low KC, Tergaonkar V (2013) Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 38:426–434. doi: 10.1016/j.tibs.2013.07.001 CrossRefPubMedGoogle Scholar
  14. Nagore E et al (2016) TERT promoter mutations in melanoma survival. Int J Cancer. doi: 10.1002/ijc.30042 PubMedGoogle Scholar
  15. Pópulo H et al (2014) TERT Promoter Mutations in Skin Cancer: the Effects of Sun Exposure and X-Irradiation. J Investig Dermatol 134:2251–2257. doi: 10.1038/jid.2014.163 CrossRefPubMedGoogle Scholar
  16. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA A Cancer J Clin 66:7–30. doi: 10.3322/caac.21332 CrossRefGoogle Scholar
  17. Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W (2014) Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet 46:1160–1165. doi: 10.1038/ng.3101 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Richard Ofner
    • 1
  • Cathrin Ritter
    • 1
    • 2
  • Barbara Heidenreich
    • 3
  • Rajiv Kumar
    • 3
  • Selma Ugurel
    • 5
  • David Schrama
    • 4
  • Jürgen C. Becker
    • 1
    • 2
    • 5
    Email author
  1. 1.Department of General DermatologyMedical University GrazGrazAustria
  2. 2.Translational Skin Cancer Research – TSCR, DKTK Partner Site Essen/Düsseldorf, German Cancer Research ConsortiumUniversity of Duisburg EssenEssenGermany
  3. 3.Division of Molecular Genetic EpidemiologyGerman Cancer Research CenterHeidelbergGermany
  4. 4.Department of DermatologyUniversity Hospital of WürzburgWürzburgGermany
  5. 5.Department of DermatologyUniversity Hospital of EssenEssenGermany

Personalised recommendations